Preferred Label : Edralbrutinib;
NCIt synonyms : BTK inhibitor TG-1701;
NCIt definition : An orally available irreversible inhibitor of Bruton's tyrosine kinase (BTK; Bruton
agammaglobulinemia tyrosine kinase) with potential antineoplastic activity. Upon administration,
edralbrutinib covalently binds to and irreversibly inhibits BTK activity, thereby
preventing the activation of the B-cell antigen receptor (BCR) signaling pathway and
BTK-mediated activation of downstream survival pathways. This may inhibit the growth
of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec
family of cytoplasmic tyrosine kinases, is overexpressed or mutated in B-cell malignancies;
it plays an important role in the development, activation, signaling, proliferation
and survival of B-lymphocytes.;
UNII : SG5I5QTR4E;
InChIKey : DNPOFZXZJJDQLB-MRXNPFEDSA-N;
CAS number : 1858206-58-2; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1858206-58-2
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : TG 1701; SHR-1459; TG-1701; SHR 1459; EBI-1459; EBI 1459;
NCI Metathesaurus CUI : CL970969;
Origin ID : C175775;
UMLS CUI : C5446734;
Semantic type(s)
- concept_is_in_subset
- has_target
